Author:
AALIF ZAHEER,OMAR AKHTAR,NARENDRANATH RAVI,BILAL MUNEER MOHAMMED,AKHVLEDIANI TAMAR
Abstract
Migraine is one of the most common and disabling diseases in the world. The usage of Calcitonin Gene-Related Peptide (CGRP) antagonist drugs has been on the horizon and looks to be a promising treatment option. Growing evidence suggests that CGRP plays a key role in the development of peripheral sensitization and associated enhanced pain. CGRP is involved in the development of neurogenic inflammation and is upregulated in inflammatory and neuropathic pain conditions. Drugs like Erenumab, Rimegepant, Olcegepant and others of the same category have shown significantly fewer side effects along with high therapeutic effects, which makes this group of drugs a useful addition to the existing therapeutic options.
Publisher
Association For Science (Publications)